Ergotamine and dihydroergotamine (DHE) were used clinically for decades before the pathophysiological basis of migraine was understood, and the mechanistic framework that emerged in the late 20th century retrospectively explained both their efficacy and their limitations. Migraine is now understood as a disorder of the trigeminovascular system, and ergot alkaloids are mechanistically coherent with three of its key pathophysiological stages: vascular dysregulation, neurogenic inflammation, and central sensitization of trigeminal pain processing.
The trigeminovascular system (TVS) encompasses the sensory trigeminal nerve fibers that innervate the pain-sensitive intracranial structures, principally the dural blood vessels, the dural sinuses, and the large pial arteries at the base of the brain. These structures are supplied by the ophthalmic division of the trigeminal nerve (cranial nerve V), whose pseudounipolar neurons have peripheral terminals on dural vessels and central projections to the trigeminal nucleus caudalis (TNC) in the brainstem. Activation of trigeminal afferents in the dura releases vasoactive neuropeptides, most prominently calcitonin gene-related peptide (CGRP), substance P, and neurokinin A, from peripheral nerve terminals through an antidromic axon reflex mechanism. CGRP is a potent vasodilator acting on CGRP receptors on dural vascular smooth muscle, producing the dural vasodilation that contributes to the pulsatile quality of migraine headache.1
Cortical spreading depression (CSD) is the electrophysiological correlate of the migraine aura. CSD is a wave of near-complete neuronal and glial depolarization that propagates across the cortex at 2–5 mm per minute, followed by prolonged suppression of neural activity. The propagating depolarization wave is associated with massive ionic redistributions, including potassium efflux and sodium, calcium, and chloride influx, and triggers the release of arachidonic acid, nitric oxide, and prostaglandins into the cortical interstitium. CSD activates trigeminal meningeal afferents, initiating the inflammatory cascade in the dura that drives the headache phase. In patients with migraine without aura, a subclinical CSD-like event has been proposed as a silent trigger for the same dural inflammatory process, though this remains an area of active investigation.2
Neurogenic inflammation in the dura is the intermediate step that links trigeminovascular activation to the sustained headache phase. Following trigeminal activation, antidromic release of CGRP, substance P, and neurokinin A from dural nerve terminals produces a local sterile inflammatory state characterized by plasma protein extravasation from dural blood vessels, mast cell degranulation, and recruitment of inflammatory mediators. This process sensitizes the peripheral trigeminal terminals, lowering their activation threshold and contributing to the allodynia and photophobia that characterize migraine attacks. Ergotamine and DHE inhibit dural plasma protein extravasation in animal models of neurogenic inflammation at doses comparable to those used clinically, an anti-inflammatory mechanism that operates in addition to cranial vasoconstriction and is shared with the triptan class.3
Central sensitization of the TNC occurs as the migraine attack progresses, and this is pharmacologically the most important concept for understanding why early treatment is so much more effective than late treatment with both ergots and triptans. As the attack continues and sustained nociceptive input arrives from the periphery, second-order neurons in the TNC develop central sensitization, manifesting clinically as cutaneous allodynia, the heightened sensitivity to normally innocuous stimuli (scalp tenderness, sensitivity to combing or touching the hair) that develops during a migraine attack in the majority of patients. Once central sensitization is established, vasoactive and anti-inflammatory interventions at the dural level become less effective, because pain is now maintained by centrally sensitized neurons whose activity does not depend on continued peripheral input. This explains why DHE and triptans work best when administered early in the attack, before cutaneous allodynia develops.4
5-HT1B receptors on dural blood vessel smooth muscle: ergot agonism produces vasoconstriction, counteracting CGRP-mediated vasodilation. 5-HT1D receptors on trigeminal nerve terminals: ergot agonism inhibits release of CGRP, substance P, and neurokinin A, attenuating neurogenic inflammation. Alpha-adrenergic receptors on dural vessels: ergot partial agonism produces additional vasoconstrictive drive beyond the serotonergic component. 5-HT1D receptors in the TNC: ergot and triptan agonism may inhibit central trigeminal pain transmission, though this mechanism is pharmacokinetically limited by blood-brain barrier penetration for most agents. The combination of peripheral vascular, anti-neuroinflammatory, and central mechanisms makes ergots broader-spectrum antimigraine agents than their predominantly vascular reputation suggests, though central sensitization once established limits all these mechanisms equally.
Ergotamine tartrate has one of the most variable and unfavorable pharmacokinetic profiles of any orally administered drug in clinical use. Its extreme first-pass hepatic extraction, highly variable gastrointestinal absorption, slow and erratic oral bioavailability, and prolonged pharmacodynamic effect that dissociates from its short plasma half-life collectively make plasma concentration-effect relationships difficult to predict, which is a primary reason why its therapeutic use has been progressively replaced by triptans in most clinical settings.
Oral bioavailability of ergotamine tartrate is exceptionally low and highly variable, ranging from less than 1% to approximately 5% across studies, with individual patient values spanning an order of magnitude. This poor oral bioavailability reflects two compounding factors: erratic and incomplete gastrointestinal absorption, and extensive hepatic first-pass extraction. Ergotamine is a substrate for the cytochrome P450 3A4 (CYP3A4) enzyme system, which is expressed at high levels in both the intestinal wall and the liver. CYP3A4 in the gut wall initiates pre-systemic metabolism before the drug even reaches the portal circulation, and the liver removes a further large fraction of what reaches the portal blood on first pass. The combination of intestinal wall CYP3A4 metabolism and hepatic first-pass extraction means that the systemic bioavailability of oral ergotamine is low and unpredictably variable among patients, depending on intestinal CYP3A4 expression levels, P-glycoprotein-mediated efflux, and the gastric motility state at the time of dosing (migraine itself delays gastric emptying, further reducing absorption).5
Rectal administration of ergotamine tartrate (as suppositories, typically 2 mg ergotamine with 100 mg caffeine as Cafergot) achieves substantially higher bioavailability than oral dosing, with mean peak plasma concentrations approximately 20-fold greater than those after equivalent oral doses in pharmacokinetic studies using sensitive HPLC assays. The rectal route bypasses a portion of the first-pass effect by delivering drug directly to the inferior and middle hemorrhoidal veins, which drain into the systemic circulation rather than the portal system, though the upper hemorrhoidal veins do drain into the portal system, so the bypass is incomplete. Caffeine, co-formulated with ergotamine in Cafergot, enhances ergotamine absorption through its effects on gastrointestinal motility and potentially through vasoconstriction of splanchnic vessels that reduces first-pass hepatic extraction; caffeine has independent vasoconstricting activity and may also contribute directly to antimigraine effect through adenosine receptor antagonism.6
The plasma half-life of ergotamine after intravenous administration is approximately 2 hours for the alpha (distribution) phase and 21 hours for the beta (elimination) phase, reflecting its large volume of distribution (approximately 1,800 mL/kg) and extensive tissue binding. The terminal elimination half-life means that ergotamine accumulates with repeated dosing far more than its short alpha-phase half-life would suggest, and plasma concentrations after the second or third dose in a day may be substantially higher than after the first. This accumulation is a major contributor to the risk of ergotism with frequent dosing. Active metabolites, including the O-demethylated metabolite of ergotamine, retain vasoconstrictive activity and contribute to prolonged pharmacodynamic effects that outlast the parent compound's plasma presence, which is why vasoconstriction persists for 24 hours or longer after a single therapeutic dose.10
Migraine attacks are associated with gastric stasis (gastroparesis), which delays gastric emptying and reduces the rate of drug absorption from the small intestine. Nausea, itself a prominent feature of migraine and a common side effect of ergotamine, further slows gastric motility. This means oral ergotamine taken at the onset of a migraine attack, when it is most pharmacologically appropriate, is absorbed most slowly and erratically. Co-administration of metoclopramide (10 mg orally or intramuscularly) before ergotamine has been advocated for this reason: metoclopramide accelerates gastric emptying, improves ergotamine absorption, and independently reduces migraine-associated nausea. This represents one of the few validated strategies for partially overcoming the pharmacokinetic limitations of oral ergotamine.
Dosing limits for ergotamine are defined not by pharmacokinetic endpoints but by cumulative vasoconstrictive toxicity risk. The maximum recommended dose in current guidelines is 6 mg per attack and 10 mg per week, limits derived from clinical experience with ergotism rather than from plasma concentration targets. Patients with frequent attacks who use ergotamine repeatedly across a week approach the chronic ergotism threshold at doses that produce apparently adequate antimigraine effect in each individual attack, because each dose adds to the residual vasoconstrictive effect of the preceding doses through both accumulation of parent drug (long beta-phase half-life) and accumulation of active vasoconstrictive metabolites. Ergotamine use on more than 10 days per month is associated with medication overuse headache (MOH), the rebound headache syndrome that develops through central sensitization and receptor downregulation at trigeminal 5-HT1 receptors.7
Dihydroergotamine mesylate (DHE) is produced by hydrogenation of the C-9/C-10 double bond of ergotamine, a structural modification that substantially changes its vascular pharmacology without abolishing its 5-HT1B/1D receptor agonism. DHE has a more favorable vascular profile than ergotamine, greater venous than arterial vasoconstrictive activity, and is available in parenteral and intranasal formulations that circumvent the severe oral bioavailability limitations of ergotamine. In the treatment of severe, refractory, or prolonged migraine attacks, DHE remains the most reliable ergot option and retains clinical utility that triptans do not fully replicate.
The oral bioavailability of DHE, like that of ergotamine, is extremely low (less than 1%) due to extensive first-pass CYP3A4 metabolism and is not clinically useful. Intramuscular (IM) administration of DHE 1 mg produces measurable plasma concentrations within 15–20 minutes, with peak concentrations at approximately 30 minutes and a terminal elimination half-life of 10–15 hours, substantially longer than the alpha-phase half-life suggests. Intravenous (IV) administration provides rapid and predictable plasma levels and is the most reliable route for hospital-based treatment of status migrainosus (migraine lasting more than 72 hours) and refractory migraine. The IV route is associated with a higher frequency of nausea than IM administration, and antiemetic pretreatment (metoclopramide 10 mg IV or prochlorperazine 10 mg IV) is standard practice before IV DHE administration to improve tolerability and potentially to add independent antimigraine benefit, since prochlorperazine and metoclopramide have direct antimigraine activity at dopamine D2 receptors in the TNC.8
Intranasal DHE (Migranal, 4 mg total dose delivered as 0.5 mg per spray, two sprays per nostril) offers a non-parenteral route with substantially better bioavailability than oral ergotamine, approximately 32–40% of that achieved by IV administration. Absorption is rapid, with peak plasma concentrations at 30–60 minutes. The main pharmacokinetic limitation of intranasal DHE is high variability in bioavailability depending on nasal mucosal status, which is reduced by nasal congestion, mucosal edema, and prior decongestant use. Newer intranasal formulation approaches targeting delivery to the upper nasal space and olfactory mucosa have been developed to improve peak concentration consistency.9
The vascular pharmacology of DHE differs from ergotamine in clinically important ways. Hydrogenation at C-9/C-10 reduces affinity and intrinsic efficacy at arterial smooth muscle alpha-adrenergic receptors while preserving 5-HT1B/1D receptor agonism and enhancing venous alpha-adrenergic activity. The result is that DHE is a more potent venoconstrictor than arterial vasoconstrictor relative to ergotamine. Venoconstriction increases venous return, activates cardiopulmonary baroreceptors, and reflexively reduces sympathetic outflow, a systemic hemodynamic mechanism proposed to contribute to antimigraine efficacy. DHE also more completely inhibits CGRP release from trigeminal terminals than ergotamine at comparable doses, which may reflect differential 5-HT1D agonism. The reduced arterial vasoconstrictive profile means DHE has a lower risk of peripheral arterial vasospasm than ergotamine, though the absolute contraindications in cardiovascular disease apply equally to both agents because residual arterial vasoconstrictive activity remains clinically significant.9
Status migrainosus is defined as a debilitating migraine attack lasting more than 72 hours, refractory to standard outpatient treatments. IV DHE, administered as 0.5–1 mg every 8 hours for 2–3 days in an inpatient or observation unit setting (the Raskin protocol), is one of the most effective treatments for this condition and remains superior to most alternatives in terms of sustained headache freedom at 48–72 hours. The protocol requires antiemetic pretreatment with metoclopramide or prochlorperazine, cardiac monitoring in patients with any cardiovascular risk factors, and contraindication screening before initiation. Triptans do not offer a comparable parenteral protocol for sustained refractory migraine, and this is a clinical situation where DHE's unique pharmacokinetic and pharmacodynamic profile provides genuine therapeutic advantage.
Subcutaneous DHE administration is not standard in the United States but is used in some countries and produces bioavailability intermediate between IM and IV routes with slower onset than IV. The pharmacodynamic duration of effect for all parenteral DHE routes is substantially longer than the plasma half-life of the parent compound, again reflecting contributions from the active metabolite 8-hydroxy-DHE (8-OH-DHE), which is the principal circulating metabolite and retains full venoconstricting and 5-HT1 agonist activity. This metabolite, formed by CYP3A4 and other oxidative pathways in the liver, reaches plasma concentrations three to four times those of the parent compound after oral dosing and approximately equal to parent compound concentrations after IV administration, making it a pharmacologically important contributor to the overall DHE effect that is not reflected in parent compound plasma assays alone.10
The contraindication profile and drug interaction risks of ergotamine and DHE are among the most clinically consequential in headache pharmacology. The absolute cardiovascular contraindications are broad, the CYP3A4 inhibitor interaction is severe and potentially life-threatening, and the ergot-triptan combination prohibition is a safety rule that must be applied without exception. Understanding the mechanisms behind each restriction is essential for safe prescribing and for recognizing and managing the toxicological syndromes that develop when these restrictions are violated.
Absolute cardiovascular contraindications to ergotamine and DHE share a common mechanistic basis: the combined alpha-adrenergic and serotonergic vasoconstrictive activity of both agents is dangerous in any vascular territory where blood flow is already compromised by atherosclerosis, vasospasm, or stenosis. Coronary artery disease (CAD), including stable angina, prior myocardial infarction (MI), coronary vasospasm (Prinzmetal angina), and history of coronary revascularization, constitutes an absolute contraindication because ergot-induced coronary vasospasm can precipitate acute MI, even in patients who have previously tolerated ergot use without incident. Peripheral vascular disease, Raynaud phenomenon, and thromboangiitis obliterans (Buerger disease) are absolute contraindications because the reduction in peripheral perfusion can precipitate digit or limb ischemia. Cerebrovascular disease and prior stroke are absolute contraindications because cranial vasoconstrictive effects can reduce collateral blood flow to ischemic territories. Uncontrolled hypertension is a contraindication because the pressor effect of ergots adds to an already elevated arterial pressure, increasing the risk of hypertensive encephalopathy and stroke.11
Pregnancy is an absolute contraindication to ergotamine and DHE in all trimesters except the specific postpartum hemorrhage context of ergonovine and methylergonovine. Uterine vasoconstriction and direct uterotonic effects on the estrogen-primed myometrium can cause fetal hypoxia, intrauterine growth restriction, and preterm labor; case reports of ergotamine use in early pregnancy are associated with increased rates of spontaneous abortion. The contraindication also extends to breastfeeding, as ergotamine is secreted in breast milk and has caused neonatal vasospasm, ergotism, and diarrhea in nursing infants at doses taken by the mother for migraine. Basilar-type migraine (migraine with brainstem aura) and hemiplegic migraine are contraindications because the risk of inducing brainstem or cortical ischemia through additional vasoconstriction in already compromised vascular territories is considered unacceptable, though the evidence base for this contraindication is largely theoretical.5
The CYP3A4 inhibitor drug interaction is the most clinically dangerous pharmacokinetic interaction in ergot prescribing. CYP3A4 is the principal enzyme responsible for ergotamine and DHE metabolism; inhibition of this enzyme dramatically increases ergot plasma concentrations, converting a therapeutic dose into a toxic one. The most potent CYP3A4 inhibitors relevant to migraine patients are macrolide antibiotics (erythromycin, clarithromycin — azithromycin is not a significant CYP3A4 inhibitor), azole antifungals (ketoconazole, itraconazole, fluconazole, voriconazole), HIV protease inhibitors (ritonavir, indinavir, nelfinavir, saquinavir), and cobicistat. Co-administration of any of these agents with ergotamine or DHE is absolutely contraindicated by FDA labeling. Case reports of ergotism precipitated by these interactions document plasma ergot concentrations ten to forty times normal therapeutic levels, with resulting severe peripheral and coronary vasospasm requiring intensive care admission and prolonged vasodilatory therapy.5
Gangrenous ergotism presents with cold, painful, pulseless extremities (most commonly fingers and toes), mottled or cyanotic skin, and absent Doppler signals in affected vessels. Proximal pulses may be present initially. Any patient on ergotamine who presents with extremity ischemia requires immediate ergot discontinuation, investigation for precipitating CYP3A4 inhibitor exposure, and vasodilatory therapy. IV nitroprusside (titrated to restore peripheral perfusion), IV prostaglandin E1 (alprostadil), and anticoagulation with heparin are the standard interventions. Alpha-adrenergic blockade with phentolamine provides partial relief of the adrenergic component but does not reverse the 5-HT2A-mediated component. In refractory cases, regional sympathetic blockade or direct intra-arterial vasodilator infusion may be required. Recovery of perfusion must be confirmed by Doppler assessment, not just clinical examination, and treatment duration must be guided by pharmacodynamic recovery, not plasma drug concentrations.
The ergot-triptan combination is contraindicated due to additive vasoconstrictive risk. Both drug classes produce cranial vasoconstriction through 5-HT1B receptor agonism, and their combination produces additive vasoconstrictive effects in coronary and peripheral arteries as well. The current FDA-mandated labeling requires a minimum 24-hour interval between any ergot-containing product and any triptan, and a 24-hour interval between any triptan and any ergot. In patients using ergotamine (with its long pharmacodynamic duration), a 24-hour interval after the last ergot dose before triptan use is the minimum; some clinicians extend this to 48 hours given the long beta-phase half-life and active metabolite contribution to ergot pharmacodynamics. Serotonin syndrome, characterized by the triad of neuromuscular abnormalities (clonus, hyperreflexia, tremor), autonomic instability (hyperthermia, tachycardia, diaphoresis), and altered mental status (agitation, confusion), is a risk when multiple serotonergic agents are combined, though the predominant concern with the ergot-triptan combination is additive vasoconstriction rather than serotonin syndrome per se, since both classes act primarily on 5-HT1 rather than 5-HT2A receptors at therapeutic doses.11
Triptans displaced ergots as the predominant specific antimigraine treatment class during the 1990s, and for most patients with episodic migraine this displacement is pharmacologically justified. However, the two classes are not simply interchangeable with triptans being the better version; they differ mechanistically, pharmacokinetically, and clinically in ways that define a residual role for ergots that is not replicated by any currently available triptan.
The shared mechanism between ergots and triptans is 5-HT1B/1D receptor agonism. Triptans are selective 5-HT1B/1D agonists, while ergots activate 5-HT1B/1D as part of their broader receptor profile. The cranial vasoconstrictive and anti-neuroinflammatory effects that both classes produce at the peripheral trigeminovascular level are mechanistically identical at these receptors. However, triptans are full agonists at 5-HT1B/1D receptors, achieving maximum receptor activation at concentrations well within the therapeutic range, while ergots are partial agonists, producing submaximal activation even at high receptor occupancy. In clinical practice, triptans produce faster and more complete headache relief in randomized controlled trials, with higher two-hour pain-free rates (40–70% for oral triptans versus 30–40% for oral ergotamine) and better tolerability profiles. The multiple triptan formulations (oral, subcutaneous, nasal spray, orally dissolving tablet) also address the challenge of migraine-associated gastroparesis more effectively than oral ergotamine.12
The critical clinical distinction favoring ergots over triptans is headache recurrence. Migraine recurrence, defined as return of headache within 24 hours of initial response to acute treatment, occurs in 20–40% of patients treated with short-acting triptans (sumatriptan, zolmitriptan, rizatriptan, almotriptan) during the 24-hour observation window. Ergotamine and DHE, because of their longer pharmacodynamic duration driven by active metabolites and tissue binding, produce substantially lower recurrence rates, with some studies reporting recurrence rates of 10–20% after DHE versus 30–40% after sumatriptan. For patients with migraine attacks that are particularly long (greater than 24 hours), frequently recurrent after triptan use, or associated with what is called the "triptan chest" (chest pressure symptom that prompts discontinuation), ergotamine or DHE may be the more appropriate specific antimigraine agent. The reduced recurrence rate with ergots reflects their sustained pharmacodynamic effect rather than superior acute efficacy, and for patients in whom recurrence is the primary clinical problem, this pharmacokinetic feature is the therapeutic advantage.13
The longer half-life and pharmacodynamic duration of ergots relative to triptans also creates a greater risk of medication overuse headache (MOH). Triptan-related MOH typically develops at use frequencies above 10 days per month, while ergot-related MOH has been reported at use frequencies as low as 6–10 days per month in susceptible patients, reflecting the greater sustained receptor desensitization produced by ergots at 5-HT1B/1D receptors. When selecting between ergots and triptans for a patient with frequent migraine attacks, this differential MOH threshold must be factored into the risk-benefit assessment. For patients who require specific antimigraine treatment more than 8–10 days per month, prophylactic therapy should be initiated regardless of the acute agent chosen, and the choice between ergots and triptans should favor triptans given the lower MOH risk profile.7
Attacks lasting longer than 24 hours: DHE's extended pharmacodynamic duration reduces the recurrence that plagues short-acting triptans in prolonged attacks. Status migrainosus: IV DHE with antiemetic pretreatment (Raskin protocol) has no established triptan equivalent for sustained refractory migraine. Frequent triptan recurrence: patients who consistently experience headache recurrence within 24 hours of triptan response are candidates for DHE as an alternative acute agent. Triptan intolerance: patients who experience significant "triptan sensations" (chest tightness, flushing, paresthesias) or are unable to use triptans due to cardiovascular risk may tolerate intranasal DHE if the cardiovascular contraindications have been carefully excluded. Cluster headache: IV and IM DHE are effective treatments for cluster headache attacks and for cluster prophylaxis in selected patients, an indication where triptans are less well established parenterally.
Screen contraindications first: cardiovascular disease, uncontrolled hypertension, pregnancy, breastfeeding, basilar or hemiplegic migraine, and concurrent CYP3A4 inhibitor use are absolute contraindications. No exceptions.
Select route for clinical context: oral ergotamine (with metoclopramide pretreatment) for moderate attacks in patients without IV access; rectal ergotamine for attacks with prominent nausea; intranasal DHE for moderate-to-severe attacks where triptan has failed or recurred; IV/IM DHE in the emergency department or observation setting for severe, refractory, or status migrainosus.
Apply dose limits rigorously: ergotamine maximum 6 mg per attack, 10 mg per week; DHE maximum 3 mg per 24 hours (IV), with careful monitoring for vasospasm symptoms.
Educate on the 24-hour rule: no triptan within 24 hours of ergot use; no ergot within 24 hours of triptan use. Document this in the chart and reinforce at every visit.
Monitor for MOH: any patient using ergot preparations more than 8–10 days per month requires prophylactic therapy and a structured plan to reduce acute medication frequency.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
doi:10.1152/physrev.00034.2015Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117(Pt 1):199–210.
doi:10.1093/brain/117.1.199Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13(8):307–311.
doi:10.1016/0165-6147(92)90097-PBurstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47(5):614–624.
doi:10.1002/1531-8249(200005)47:5%3C614::AID-ANA9%3E3.0.CO;2-NTfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123(1):9–18.
doi:10.1093/brain/123.1.9Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol. 1983;16(6):695–699.
doi:10.1111/j.1365-2125.1983.tb02243.xDiener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004;3(8):475–483.
doi:10.1016/S1474-4422(04)00824-5Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995–997.
doi:10.1212/WNL.36.7.995Tfelt-Hansen PC, Koehler PJ. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache. 2011;51(5):752–778.
doi:10.1111/j.1526-4610.2011.01892.xMuller-Schweinitzer E. Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol. 1984;26(6):699–705.
doi:10.1007/BF00541928Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–762.
doi:10.1212/WNL.55.6.754Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–1675.
doi:10.1016/S0140-6736(01)06711-3Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KM, eds. The Headaches. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:399–409.